Masaki Setoguchi - Concepedia

Author

Masaki Setoguchi

Daiichi-Sankyo (Japan)

Also Known As

M. SETOGUCHI, Masaki Setoguchi

Publications

138

Citations

H-Index

Concepts

All Affiliations

Daiichi-Sankyo (Japan)Daiichi Sankyo (Germany)

About

Masaki Setoguchi is an author at Daiichi-Sankyo (Japan) specializing in pharmacotherapy, medicinal chemistry, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	89
2	Pharmacology	5	5	89
3	Natural Sciences	2	2	35
4	Biochemistry	2	2	35
5	Immunology	1	1	25

Masaki Setoguchi

Publications

133

Citations

H-Index

Page 1

	Year	Citations
Discovery of <i>trans</i>-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4<i>S</i>)-methoxy-(2<i>S</i>)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist Fumihito Muro, Shin Iimura, Yuuichi Sugimoto, Journal of Medicinal Chemistry Pharmaceutical ScienceImmunologyOrally ActivePeptide ScienceImmunotherapeutics	2009	25
Chiral synthesis of the CD ring unit of paclitaxel from d-glucal Takayuki Momose, Masaki Setoguchi, Toshiki Fujita, Chemical Communications	2000	24
A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Bioorganic & Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceMedicineMechanism Of ActionPharmacological Agent	2012	23
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma Dimpy Koul, Shuzhen Wang, Shaofang Wu, Oncotarget	2017	20
A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda, Bioorganic & Medicinal Chemistry Medicinal ChemistryMedicineTrans-4-substituted Cyclohexanecarboxylic AcidPharmacological AgentPharmacotherapy	2008	18
Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Bioorganic & Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceMedicineMechanism Of ActionPharmacological Agent	2011	13
Identification of 4-[1-[3-chloro-4-[N’-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda, Bioorganic & Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceBioorganic ChemistryBiochemistry	2008	10

Page 1